What Is End-of-Life Care Like for Advanced Primary Peritoneal Carcinoma?
By CRYSTAL BAI •
The short answer: Primary peritoneal carcinoma (PPC) is a rare gynecologic cancer arising from the peritoneum rather than the ovary, but treated similarly to ovarian cancer. In advanced or recurrent stages, end-of-life care focuses on managing ascites, bowel obstruction, pain, and fatigue. Early palliative care integration significantly improves quality of life.
Understanding Primary Peritoneal Carcinoma
Primary peritoneal carcinoma (PPC) is a malignancy that originates in the cells lining the abdominal cavity (peritoneum) and is biologically and clinically similar to high-grade serous ovarian cancer (HGSOC). It often shares the same BRCA mutations, responds to similar treatments, and has a similar overall course.
PPC is often diagnosed at an advanced stage because it arises diffusely across the peritoneum rather than from a discrete tumor mass. Like advanced ovarian cancer, it typically responds well to initial chemotherapy but frequently recurs.
Advanced PPC: Key Symptom Challenges
In advanced or platinum-resistant PPC, the peritoneal burden creates distinctive symptoms:
- Ascites (abdominal fluid): Often massive, causing pressure, bloating, breathlessness, early satiety, and discomfort — the most common and distressing symptom of advanced PPC
- Malignant bowel obstruction (MBO): A serious complication of peritoneal disease; occurs in up to 50% of women with advanced gynecologic cancer
- Pain: Abdominal and pelvic pain from tumor burden, adhesions, or invasion
- Nausea and vomiting: From bowel involvement, ascites pressure, or opioid side effects
- Fatigue: Often profound in advanced disease
- Nutritional decline: Early satiety from ascites and bowel dysfunction leads to significant weight loss
Palliative Management Strategies
- Ascites management: Serial paracentesis (drainage) every 2-4 weeks; tunneled abdominal drainage catheters (TIPPS/Pleuro-Evac) allow drainage at home; diuretics have limited efficacy in malignant ascites
- Malignant bowel obstruction: Medical management with octreotide, dexamethasone, and antiemetics; venting nasogastric tubes; surgical intervention rarely appropriate in advanced disease
- Pain management: Multimodal analgesia; opioid rotation if side effects limiting; celiac plexus block for refractory abdominal pain
- Nutritional support: Focus on comfort eating rather than aggressive nutrition; TPN rarely appropriate in the end-of-life setting
- Psychosocial support: PPC affects predominantly women; body image changes from ascites and weight loss; anxiety about recurrence
Advance Care Planning for PPC
Key decisions for women with advanced PPC to address in advance include: preferences around repeated hospitalizations for bowel obstruction (surgery vs. medical management vs. comfort focus), goals for the ascites management (active drainage vs. allowing natural progression), and desired place of death. A death doula can help navigate these complex decisions and coordinate with gynecologic oncology and palliative care teams.
Frequently Asked Questions
What is the prognosis for primary peritoneal carcinoma?
PPC has a similar prognosis to high-grade serous ovarian cancer. Five-year survival rates range from 20-40% for advanced disease, with many women experiencing disease recurrence after initial response to chemotherapy. PARP inhibitor maintenance therapy has extended progression-free survival in BRCA-mutated cases.
Is primary peritoneal carcinoma the same as ovarian cancer?
PPC is biologically similar to high-grade serous ovarian cancer and is treated with the same protocols. The key difference is its origin — PPC arises from the peritoneal lining rather than the ovary itself, which is relevant because ovaries may appear normal or minimally involved at diagnosis. Outcomes and treatment are generally similar.
How is ascites managed in advanced primary peritoneal carcinoma?
Malignant ascites in PPC is most effectively managed with paracentesis — draining fluid through a needle or catheter. For patients requiring frequent drainage (every 1-3 weeks), tunneled drainage catheters (like the PleurX system) allow home drainage without repeated hospital visits. Diuretics have limited effectiveness for malignant ascites.
What is malignant bowel obstruction and how is it treated?
Malignant bowel obstruction (MBO) occurs when tumor or adhesions block the bowel, causing nausea, vomiting, pain, and inability to eat or pass stool. In advanced cancer, medical management (somatostatin analogues like octreotide, steroids, antiemetics) is preferred over surgery. Comfort-focused management allows patients to stay at home or in hospice rather than hospitalized.
When should hospice be considered for primary peritoneal carcinoma?
Hospice becomes appropriate when disease-directed treatment is no longer providing meaningful benefit and prognosis is estimated at 6 months or less. For many PPC patients, this occurs when the cancer becomes platinum-resistant and multiple lines of therapy have been tried. Early hospice enrollment — before a crisis — allows better symptom management and quality of life.
Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.